

X-VIVO™ Media use for Car-T

Brentjens, R. J., Riviere, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., . . . Sadelain, M. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. *Blood*, 118(18), 4817-4828. doi:10.1182/blood-2011-04-348540

Moon, E. K., Carpenito, C., Sun, J., Wang, L. S., Kapoor, V., Predina, J., . . . Albelda, S. M. (2011). Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor. *Clinical Cancer Research*, 17(14), 4719-4730. doi:10.1158/1078-0432.ccr-11-0351

Schalkwyk, M. C., Papa, S. E., Jeannon, J., Urbano, T. G., Spicer, J. F., & Maher, J. (2013). Design of a Phase I Clinical Trial to Evaluate Intratumoral Delivery of ErbB-Targeted Chimeric Antigen Receptor T-Cells in Locally Advanced or Recurrent Head and Neck Cancer. *Human Gene Therapy Clinical Development*, 24(3), 134-142. doi:10.1089/humc.2013.144

Singh, H., Figliola, M. J., Dawson, M. J., Olivares, S., Zhang, L., Yang, G., . . . Cooper, L. J. (2013). Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. *PLoS ONE*, 8(5). doi:10.1371/journal.pone.0064138